Overview

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

Status:
Withdrawn
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide
Glimepiride